Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

Inclusion Criteria Patients must have: * Diagnosis of AIDS and persistent Mycobacterium avium- intracellulare (MAI) bacillemia. * Life expectancy of at least 3 months. * Baseline chest X-ray and EKG (electrocardiogram). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Known hypersensitivity to interferons or other exogenous lymphokine. * History of cardiac abnormality or disease. * History of hypertension. Patients with the following are excluded: * Known hypersensitivity to interferons or other exogenous lymphokine. * History of cardiac abnormality or disease. * History of hypertension. Prior Medication: Excluded within 4 weeks of study entry: * Corticosteroids. * Anti-inflammatory medication (except aspirin). * Changes in the dose of anti-mycobacterial drugs. * Immune agents. Prior Treatment: Excluded within 4 weeks of study entry: * Radiotherapy. Risk Behavior: Excluded: * Intravenous drug abuse.